These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 12793407)

  • 21. Prostate specific-antigen distribution in asymptomatic Canadian men with no clinical evidence of prostate cancer.
    Chun FK; Perrotte P; Briganti A; Benayoun S; Lebeau T; Ramirez A; Lewinshtein DJ; Valiquette L; Guay JP; Karakiewicz PI
    BJU Int; 2006 Jul; 98(1):50-3. PubMed ID: 16831142
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of percent free prostate specific antigen as a predictor of prostate cancer detection on repeat biopsy.
    Uemura H; Nakamura M; Hasumi H; Sugiura S; Fujinami K; Miyoshi Y; Yao M; Kubota Y
    Int J Urol; 2004 Jul; 11(7):494-500. PubMed ID: 15242358
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Strip test for the quick detection of increased concentrations of prostate-specific antigen in blood.
    Lein M; Jung K; Schnorr D; Henke W; Loening SA
    Eur J Clin Chem Clin Biochem; 1996 Jun; 34(6):511-4. PubMed ID: 8831055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/mL.
    Canby-Hagino E; Hernandez J; Brand TC; Troyer DA; Higgins B; Ankerst DP; Thompson IM; Leach RJ; Parekh DJ
    Urology; 2007 Oct; 70(4):748-52. PubMed ID: 17991549
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The electromagnetic detection of prostatic cancer: evaluation of diagnostic accuracy.
    Tubaro A; De Nunzio C; Trucchi A; Stoppacciaro A; Miano L
    Urology; 2008 Aug; 72(2):340-4. PubMed ID: 18336888
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial.
    Määttänen L; Hakama M; Tammela TL; Ruutu M; Ala-Opas M; Juusela H; Martikainen P; Stenman UH; Auvinen A
    Br J Cancer; 2007 Jan; 96(1):56-60. PubMed ID: 17213825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 28. On call. I've been tracking my PSA ever since I turned 50, 11 years ago. Since I just moved from St. Louis to Denver, my next test will be done in a new lab. Will the change in labs affect my levels?
    Simon HB
    Harv Mens Health Watch; 2009 Nov; 14(4):8. PubMed ID: 20014498
    [No Abstract]   [Full Text] [Related]  

  • 29. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.
    Thompson IM; Pauler Ankerst D; Chi C; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
    J Clin Oncol; 2007 Jul; 25(21):3076-81. PubMed ID: 17634486
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assay standardization bias: different prostate cancer detection rates and clinical outcomes resulting from different assays for free and total prostate-specific antigen.
    Sotelo RJ; Mora KE; Pérez LH; Novoa J; Carmona O; De Andrade R; Borges RE; Parada D; Loeb S; Catalona WJ
    Urology; 2007 Jun; 69(6):1143-6. PubMed ID: 17572203
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early detection of prostate cancer with low PSA cut-off values leads to significant stage migration in radical prostatectomy specimens.
    Berger AP; Spranger R; Kofler K; Steiner H; Bartsch G; Horninger W
    Prostate; 2003 Oct; 57(2):93-8. PubMed ID: 12949932
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.
    Khan MA; Partin AW; Rittenhouse HG; Mikolajczyk SD; Sokoll LJ; Chan DW; Veltri RW
    J Urol; 2003 Sep; 170(3):723-6. PubMed ID: 12913682
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Baseline prostate-specific antigen level and risk of prostate cancer and prostate-specific mortality: diagnosis is dependent on the intensity of investigation.
    Connolly D; Black A; Gavin A; Keane PF; Murray LJ
    Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):271-8. PubMed ID: 18250343
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial.
    Pinsky PF; Crawford ED; Kramer BS; Andriole GL; Gelmann EP; Grubb R; Greenlee R; Gohagan JK
    BJU Int; 2007 Apr; 99(4):775-9. PubMed ID: 17223921
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Percent positive biopsy cores as a prognostic factor for prostate cancer treated with external beam radiation.
    Spalding AC; Daignault S; Sandler HM; Shah RB; Pan CC; Ray ME
    Urology; 2007 May; 69(5):936-40. PubMed ID: 17482938
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive criteria for prostate cancer detection in men with serum PSA concentration of 2.0 to 4.0 ng/mL.
    Kravchick S; Peled R; Dorfman D; Agulansky L; Ben-Dor D; Cytron S
    Urology; 2005 Sep; 66(3):542-6. PubMed ID: 16140074
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ratios of free to total prostate-specific antigen and total prostate specific antigen to protein concentrations in saliva and serum of healthy men.
    Ayatollahi H; Darabi Mahboub MR; Mohammadian N; Parizadeh MR; Kianoosh T; Khabbaz Khoob M; Kamalian F
    Urol J; 2007; 4(4):238-41. PubMed ID: 18270950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Correct use of prostate-specific antigen in office practice].
    Desfemmes FR; Deligne E; Ghoundale O; Labarthe P; Berlizot P; Houlgatte A
    Prog Urol; 2008 Jan; 18(1):41-5. PubMed ID: 18342155
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostate cancer detection in men with a 'normal' total prostate-specific antigen (PSA) level using percentage free PSA: a prospective screening study.
    Rowe EW; Laniado ME; Walker MM; Patel A
    BJU Int; 2005 Jun; 95(9):1249-52. PubMed ID: 15892810
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a new nomogram for predicting the probability of a positive initial prostate biopsy in Japanese patients with serum PSA levels less than 10 ng/mL.
    Kawamura K; Suzuki H; Kamiya N; Imamoto T; Yano M; Miura J; Shimbo M; Suzuki N; Nakatsu H; Ichikawa T
    Int J Urol; 2008 Jul; 15(7):598-603. PubMed ID: 18462353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.